Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug-Eluting Stents | 13 | 2018 | 53 | 3.630 |
Why?
|
| Myocardial Infarction | 23 | 2015 | 485 | 2.180 |
Why?
|
| Stents | 14 | 2017 | 192 | 1.660 |
Why?
|
| Coronary Artery Disease | 9 | 2015 | 458 | 1.510 |
Why?
|
| Sirolimus | 8 | 2018 | 63 | 1.410 |
Why?
|
| Coronary Restenosis | 10 | 2013 | 38 | 1.230 |
Why?
|
| Paclitaxel | 8 | 2013 | 82 | 1.200 |
Why?
|
| Registries | 13 | 2016 | 306 | 1.100 |
Why?
|
| Absorbable Implants | 3 | 2018 | 33 | 1.050 |
Why?
|
| Coronary Stenosis | 2 | 2013 | 37 | 0.980 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 27 | 0.980 |
Why?
|
| Immunoglobulin Fab Fragments | 5 | 2006 | 28 | 0.790 |
Why?
|
| Metals | 4 | 2013 | 21 | 0.730 |
Why?
|
| Treatment Outcome | 25 | 2018 | 3173 | 0.720 |
Why?
|
| Antibodies, Monoclonal | 5 | 2006 | 211 | 0.670 |
Why?
|
| Time Factors | 17 | 2015 | 2105 | 0.630 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2005 | 41 | 0.630 |
Why?
|
| Humans | 56 | 2017 | 29292 | 0.590 |
Why?
|
| Hemostatic Techniques | 3 | 2006 | 16 | 0.590 |
Why?
|
| Radial Artery | 5 | 2016 | 23 | 0.570 |
Why?
|
| Coronary Thrombosis | 6 | 2010 | 29 | 0.570 |
Why?
|
| Postural Balance | 2 | 2016 | 128 | 0.550 |
Why?
|
| Hospitals | 2 | 2016 | 73 | 0.540 |
Why?
|
| Coronary Artery Bypass | 5 | 2011 | 114 | 0.530 |
Why?
|
| Male | 43 | 2016 | 18658 | 0.500 |
Why?
|
| Female | 43 | 2016 | 18970 | 0.500 |
Why?
|
| Aged | 32 | 2016 | 10068 | 0.500 |
Why?
|
| Pesticides | 2 | 2016 | 241 | 0.490 |
Why?
|
| Occupational Exposure | 2 | 2016 | 290 | 0.480 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 279 | 0.480 |
Why?
|
| Femoral Artery | 5 | 2013 | 55 | 0.470 |
Why?
|
| Saphenous Vein | 3 | 2007 | 28 | 0.470 |
Why?
|
| Middle Aged | 38 | 2016 | 11572 | 0.460 |
Why?
|
| Transients and Migrants | 2 | 2016 | 382 | 0.460 |
Why?
|
| Coronary Disease | 4 | 2006 | 241 | 0.420 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 26 | 0.410 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2010 | 75 | 0.400 |
Why?
|
| Myocardial Contraction | 1 | 2010 | 99 | 0.400 |
Why?
|
| Myocardial Revascularization | 5 | 2009 | 47 | 0.400 |
Why?
|
| Hemorrhage | 4 | 2016 | 105 | 0.390 |
Why?
|
| Hospital Mortality | 8 | 2014 | 200 | 0.390 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 192 | 0.370 |
Why?
|
| Hispanic Americans | 2 | 2016 | 1129 | 0.360 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 259 | 0.360 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 233 | 0.340 |
Why?
|
| Stroke Volume | 1 | 2010 | 325 | 0.340 |
Why?
|
| Contrast Media | 1 | 2006 | 141 | 0.310 |
Why?
|
| Diabetic Angiopathies | 2 | 2005 | 159 | 0.300 |
Why?
|
| Vascular Diseases | 4 | 2011 | 72 | 0.290 |
Why?
|
| Punctures | 2 | 2009 | 38 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2011 | 71 | 0.280 |
Why?
|
| Thrombosis | 3 | 2017 | 66 | 0.280 |
Why?
|
| Kidney Diseases | 1 | 2006 | 241 | 0.270 |
Why?
|
| Anticoagulants | 3 | 2008 | 135 | 0.260 |
Why?
|
| Heparin | 2 | 2008 | 83 | 0.260 |
Why?
|
| Risk Factors | 13 | 2016 | 3732 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2012 | 97 | 0.240 |
Why?
|
| Electrocardiography | 4 | 2015 | 576 | 0.240 |
Why?
|
| Risk Assessment | 11 | 2016 | 1370 | 0.230 |
Why?
|
| United States | 11 | 2016 | 3756 | 0.230 |
Why?
|
| Retreatment | 3 | 2013 | 51 | 0.220 |
Why?
|
| Retrospective Studies | 16 | 2014 | 2981 | 0.220 |
Why?
|
| Polymers | 3 | 2018 | 71 | 0.220 |
Why?
|
| Incidence | 9 | 2010 | 1168 | 0.210 |
Why?
|
| Acute Coronary Syndrome | 3 | 2011 | 177 | 0.200 |
Why?
|
| Stroke | 3 | 2013 | 545 | 0.190 |
Why?
|
| Logistic Models | 6 | 2016 | 783 | 0.180 |
Why?
|
| Follow-Up Studies | 11 | 2012 | 2198 | 0.170 |
Why?
|
| Propensity Score | 2 | 2013 | 33 | 0.160 |
Why?
|
| Prosthesis Design | 2 | 2013 | 95 | 0.160 |
Why?
|
| Coronary Occlusion | 1 | 2015 | 3 | 0.150 |
Why?
|
| Peptides | 2 | 2006 | 110 | 0.150 |
Why?
|
| Coronary Vessels | 2 | 2008 | 191 | 0.150 |
Why?
|
| Congresses as Topic | 1 | 2015 | 44 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 50 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 66 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2016 | 938 | 0.140 |
Why?
|
| North Carolina | 4 | 2016 | 1750 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 128 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 108 | 0.140 |
Why?
|
| Pediatrics | 1 | 2015 | 118 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 21 | 0.130 |
Why?
|
| Curriculum | 1 | 2015 | 205 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2013 | 34 | 0.130 |
Why?
|
| Length of Stay | 2 | 2011 | 295 | 0.120 |
Why?
|
| Medicare | 1 | 2013 | 181 | 0.120 |
Why?
|
| Angioplasty | 1 | 2011 | 23 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 53 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 74 | 0.110 |
Why?
|
| Myocardium | 2 | 2010 | 241 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 818 | 0.110 |
Why?
|
| Dobutamine | 1 | 2010 | 51 | 0.100 |
Why?
|
| Troponin | 1 | 2010 | 79 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2010 | 773 | 0.100 |
Why?
|
| Recurrence | 4 | 2013 | 237 | 0.100 |
Why?
|
| Age Factors | 1 | 2013 | 1185 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2006 | 565 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 600 | 0.100 |
Why?
|
| Urinalysis | 1 | 2009 | 18 | 0.100 |
Why?
|
| Proteinuria | 1 | 2009 | 64 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2010 | 214 | 0.090 |
Why?
|
| Angina Pectoris | 1 | 2008 | 26 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2009 | 148 | 0.090 |
Why?
|
| Fibrinogen | 1 | 2008 | 51 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2008 | 20 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 63 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2008 | 61 | 0.090 |
Why?
|
| Health Services Research | 1 | 2008 | 70 | 0.090 |
Why?
|
| Embolism | 1 | 2007 | 7 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 77 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2007 | 23 | 0.090 |
Why?
|
| Angioplasty, Balloon | 1 | 2007 | 30 | 0.090 |
Why?
|
| Thoracic Surgery | 1 | 2006 | 5 | 0.090 |
Why?
|
| Angina, Unstable | 1 | 2006 | 20 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 259 | 0.080 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 19 | 0.080 |
Why?
|
| Automation | 1 | 2006 | 29 | 0.080 |
Why?
|
| Prognosis | 5 | 2009 | 1435 | 0.080 |
Why?
|
| Injections | 1 | 2006 | 66 | 0.080 |
Why?
|
| Hemostasis, Surgical | 1 | 2006 | 14 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2011 | 645 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2006 | 43 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2006 | 105 | 0.080 |
Why?
|
| Survival Rate | 4 | 2012 | 857 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2005 | 62 | 0.080 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 121 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 3924 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2005 | 69 | 0.070 |
Why?
|
| Cardiology | 1 | 2005 | 77 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2005 | 57 | 0.070 |
Why?
|
| Adult | 3 | 2016 | 8719 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2016 | 488 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 552 | 0.070 |
Why?
|
| Cocaine | 1 | 2007 | 264 | 0.070 |
Why?
|
| Immunosuppressive Agents | 3 | 2012 | 186 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 303 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2005 | 203 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 317 | 0.070 |
Why?
|
| Hematoma | 1 | 2003 | 23 | 0.060 |
Why?
|
| Hirudins | 2 | 2016 | 23 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 257 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 157 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 153 | 0.060 |
Why?
|
| Ticlopidine | 2 | 2012 | 18 | 0.060 |
Why?
|
| Aspirin | 2 | 2012 | 63 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2015 | 148 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 44 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 703 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2016 | 519 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 1102 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 674 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2009 | 148 | 0.040 |
Why?
|
| Antithrombins | 1 | 2016 | 6 | 0.040 |
Why?
|
| Catheterization, Peripheral | 1 | 2016 | 27 | 0.040 |
Why?
|
| Radiography, Interventional | 1 | 2015 | 39 | 0.040 |
Why?
|
| Arizona | 1 | 2015 | 7 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2008 | 480 | 0.040 |
Why?
|
| Prevalence | 2 | 2008 | 974 | 0.040 |
Why?
|
| Probability | 2 | 2005 | 161 | 0.040 |
Why?
|
| Professional Competence | 1 | 2014 | 17 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 904 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 387 | 0.030 |
Why?
|
| Health Resources | 1 | 2013 | 31 | 0.030 |
Why?
|
| American Heart Association | 1 | 2012 | 95 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 391 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 55 | 0.030 |
Why?
|
| Safety | 1 | 2011 | 88 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2014 | 302 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2011 | 261 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2006 | 1764 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 145 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2008 | 5 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 43 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2008 | 17 | 0.020 |
Why?
|
| Anesthesia, Conduction | 1 | 2008 | 30 | 0.020 |
Why?
|
| Necrosis | 1 | 2008 | 58 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 229 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 54 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2008 | 61 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 36 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 63 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 2007 | 18 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2008 | 173 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 165 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2006 | 15 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 200 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 476 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2006 | 23 | 0.020 |
Why?
|
| Intracranial Hemorrhages | 1 | 2005 | 33 | 0.020 |
Why?
|
| Comorbidity | 1 | 2007 | 554 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2005 | 84 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 245 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2004 | 51 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2005 | 118 | 0.020 |
Why?
|
| Risk | 1 | 2005 | 312 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 275 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2008 | 790 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 426 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 2036 | 0.010 |
Why?
|